American Bio Medica signs sales deal with Abbott:
This article was originally published in Clinica
American Bio Medica has signed a four-year worldwide sales and marketing agreement with Abbott Laboratories for American Bio Medica's secure, on-site Rapid Drug Screen products, which simultaneously test for a panel of nine drugs of abuse. The deal is a continuation of the agreement which the Hudson, New York-based American Bio Medica had with International Murex. Murex was acquired by Abbott in April 1998.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.